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Summary: 
Background:  Delivering high quality and evidence based healthcare to deprived sectors 
of the community is a major goal for society. We investigated the effectiveness of a 
culturally sensitive enhanced care package in UK general practice in improving 
cardiovascular risk factors in South Asian patients with type 2 diabetes.  
Methods:  21 inner city practices were randomised to intervention (enhanced practice 
nurse time, link worker and diabetes specialist nurse support) (n=868) or control (standard 
care) (n=618) groups. Prescribing algorithms with clearly defined targets were provided 
for all practices. Main outcome measures comprised changes in blood pressure, total 
cholesterol and glycaemic control (HbA1c) after 2 years.  
Findings:  At baseline, groups were similar with respect to age, sex and cardiovascular 
risk factors.   
Comparing treatment groups, after adjustment for confounders, and clustering, differences 
in diastolic blood pressure (1.91mmHg, P=0.0001) and mean arterial pressure 
(1.36mmHg, P=0.0180) were significant. There were no significant differences between 
groups for total cholesterol or HbA1c. Economic analysis indicates the nurse-led 
intervention was not cost-effective. 
Across the whole study population systolic blood pressure, diastolic blood pressure and 
cholesterol decreased significantly by 4.9mmHg, 3.8mmHg and 0.45mmol/L respectively, 
but there was no change in HbA1c. 
Interpretation:  Additional, although limited, benefits were observed from our culturally 
enhanced care package over and above the secular changes achieved in the UK in recent 
years. Stricter targets in general practice and further measures to motivate patients are 
needed to maximise healthcare outcomes in South Asian patients with diabetes. 
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Introduction:  
Patients of South Asian ethnic background (United Kingdom (UK) decennial census 
categories Indian, Pakistani, Bangladeshi and other Asians) with type 2 diabetes present 
special management challenges1, 2. In the UK, the prevalence of type 2 diabetes is 4 to 6 
fold higher amongst South Asians3, onset may be over a decade earlier, there is a higher 
risk of cardiovascular and renal complications, with higher morbidity and 50% higher 
mortality compared to white Europeans4. Healthcare delivery in this population is more 
challenging because of cultural, communication and comprehension difficulties which 
along with social deprivation further complicate the achievement of defined targets5, 6. 
Payments for UK general practices based on their achievement of quality (Quality and 
Outcomes Framework-QOF)7 targets do not distinguish different ethnic groups. 
 
Community based enhanced care packages have been associated with improved metabolic 
outcomes in certain ethnic groups8 but have not been fully evaluated in large randomised 
controlled trials. Such trials are lacking in people of South Asian ethnicity9. The United 
Kingdom Asian Diabetes Study (UKADS) is an evaluation of a community based 
complex intervention aimed at reducing cardiovascular risk in South Asians with type 2 
diabetes. The intervention package tailored to the needs of the South Asian community 
comprises protected additional practice nurse time, Asian link workers and diabetes 
specialist nurse input, working to protocols to achieve clearly defined targets. In line with 
recognised complex intervention evaluations10 and following a protocol informed by a 
pilot study11 we describe a large cluster randomised controlled trial that began in 2004. 
The UKADS study hypothesis was that an enhanced care package for diabetes, would 
improve cardiovascular risk profile in patients of South Asian origin, with established 
Type 2 diabetes. 
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Methods: 
Twenty-one General Practices (seven in Coventry, and fourteen in Birmingham, UK) with 
a very high proportion of South Asians were included in the study. Nine practices were 
randomised to enhanced (intervention) and twelve to conventional (control) care; a 
common treatment algorithm was provided.  All adult patients with type 2 diabetes were 
eligible for inclusion in the study. 
Protocol and targets 
Enhanced care included an additional practice nurse session ( 4 hours) per week supported 
by link workers and a community diabetes specialist nurse. Patients in the intervention 
group were followed up on average every two months in weekly clinics run by the practice 
nurses. Practice nurses worked with primary care physicians to implement the protocol 
and encourage appropriate prescribing, provide face-to-face patient education in clinic 
setting and achieve targets for blood pressure, lipid and glycaemic control. Each patient 
was contacted by a link worker before and between appointments to encourage clinic 
attendance. In addition, link workers provided interpretation and additional educational 
input to the patients in the community setting in local languages to improve compliance 
and understanding and to encourage dietary and lifestyle changes. The community 
diabetes specialist nurse attended some of the research clinics and provided additional 
educational and clinical support, including insulin initiation, to the practice teams. All 
staff had formal training and experience in delivering diabetes care in the practice setting. 
The standard of care provided by the practice nurse and the link worker was monitored by 
the specialist nurse in regularly observed sessions. 
Practices were encouraged to adhere to treatment protocols and to achieve targets. The 
study targets followed internationally accepted norms and were HbA1c 7.0% (accepted 
target at the time of commencement of study), total Cholesterol  4.0 mmol/l (160mg/dl) 
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and blood pressure 130/80 mmHg if no microvascular complications (as recommended by 
the Joint British Societies and international bodies)12-14 and 125/75 mmHg if 
microalbuminuria or proteinuria was present.  Control practices received the same 
treatment protocols and the practices managed patients with their existing resources. The 
study protocol was approved by East Birmingham and Coventry Primary Care Trust 
Ethical Committees. Graphical representation of components and timings of the complex 
intervention are outlined in figure 115. 
Primary outcomes were follow-up measurements for blood pressure, total cholesterol and 
HbA1c, with secondary outcomes waist circumference, body mass index (BMI) and 
Framingham 10 years Coronary Heart Disease (CHD) risk score16, microalbuminuria and 
plasma creatinine. 
Passive monitoring was undertaken for adverse events and practices were encouraged to 
report any incidents related to the intervention. 
Sample size estimation and power  
This was a cluster randomized trial with general practice the unit of randomisation. 
Sample size estimations were made based on the observed differences and intra-class 
correlations (ICC-defined as between groups/ within groups variance) from the pilot study 
or an ICC = 0.05, which is derived from published estimates for primary care studies17, 18. 
In all estimations, power was set to 80%, and the 2-sided probability value to P=0.05. 
Estimates were made for differences in changes in systolic blood pressure (7mmHg, with 
standard deviation (s.d.) 21.25 and ICC=0.035), total cholesterol (0.45mmol/l, s.d.=1.1, 
ICC=0.05) and HbA1c (0.75, s.d=2.1, ICC= 0.05). All estimates from above data values 
resulted in 16-18 clusters of 80-100 patients being needed allowing for 10% drop-out rate, 
as observed  in the pilot study. Rationale for these effect sizes was that they were similar 
 - 6 -
to those observed in the pilot study, changes of this magnitude would be clinically 
significant and also they reflected prescribing algorithm targets. 
 
Statistical methods 
Data were analysed using the SAS software package. Baseline variables were compared 
between groups using χ2 tests of independence, with t-tests for continuous variables, 
which were first assessed for normality.  
Primary and  secondary outcomes were continuous. In the main intervention evaluation, 
final measured outcomes were modelled, with grand mean centred baseline measures 
included as covariates. To adjust for clustering and potential confounding effects, the SAS 
PROC MIXED procedure was used to fit hierarchical, combined fixed and random effects 
models19, 20. In all cases, mixed models included fixed effects for area (Birmingham vs. 
Coventry), gender, age at diagnosis of diabetes, duration of diabetes and corresponding 
grand mean centred baseline measurement. For HbA1c, treatment with insulin at baseline 
was included in final models. Terms for anti-hypertensive treatments, angiotensin-
converting enzyme inhibitors (ACE) or angiotensin receptor blockers (ARB) at baseline 
were included in blood pressure models. For total cholesterol, statins and fibrates were 
included. Random effects were fitted, within a subject term for General Practice, allowing 
for different intercepts and regression slopes for each individual practice (random 
coefficients models) .  
Restricted maximum likelihood models (REML) models were used to analyse data. The 
correlation structure used in reported results was “unstructured” in all cases; “Variance 
components” structures were considered. SAS graphics options were used to plot and 
evaluate residuals and influential data points, which were then removed and models re-
run; results presented do not exclude outliers. 
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For the main intention to treat analysis comparing outcomes, all patients were included. 
Baseline and 2 year follow-up data measurements were analysed; for patients whose 
follow-up data were not available (Fig. 2), data imputation using last observation carried 
forward (LOCF) was used. This was an interim value measured after one year, for around 
50% of cases, or the baseline value. Analyses using the same final models were performed 
using only subjects with complete data and using only patients who had not died; whilst 
estimates of effect differed slightly, results and their interpretation were essentially the 
same. 
Detailed data on staff salaries, travel and subsistence, equipment costs, payment to 
practices, and prescribing were collected to estimate the net intervention cost over a 2 year 
period. Changes in Quality Adjusted Life Years (QALY) between intervention and control 
groups were measured using EQ5D questionnaire21. 
Authors with access to data for analysis were NR, SB, PO’H, AHB, AS, and AG. The 
decision to submit the manuscript was made by all authors and the UKADS Study group. 
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Results: 
Patient demographics and baseline risk factors 
1486 patients of South Asian ethnicity, with established type 2 diabetes, consented to take 
part and were included in the study; 500 (33.7%) from Coventry and 986 (66.3%) from 
Birmingham.  
Baseline risk factor profile, comparing the intervention and control groups, is shown in 
Table 1. Mean age for the whole group was 57.0 years, standard deviation (SD) 11.9. 
Differences observed between groups for gender, age, duration of diabetes and diabetes 
treatment modalities were not statistically significant. Current smoking prevalence (15%) 
was similar in both groups, but more control patients were ex-smokers. There were no 
differences in weight, body mass index (BMI) or waist circumference measurements. 
Significantly more intervention than control patients were treated with statins (Table 1). 
At baseline, 268 (18%) patients had evidence of existing CHD or prior cardiovascular 
events; angina, myocardial infarction, cardiovascular accident, coronary artery bypass 
graft or other heart problems, comprising 150 (17%) intervention and 118 (19 %) control 
patients.  
Urinary albumin:creatinine ratio was measured for 1389 (93%) patients and micro-
albuminuria (defined as a ratio >2.5 in males and >3.5 in females) was present in 268 
(19%) patients. Significant proteinuria, defined as albumin:creatinine ratio of >25.0 was 
detected in 114 patients (8%). The prevalence of combined microalbuminuria or 
proteinuria was 28% , with no difference between intervention and control groups.   
Using the Framingham equation, mean (s.d) 10 year CHD risk score was 10.6 (8.8) with 
no difference between treatment groups (Table 1). 
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Effect of intensive control for 2 years  
During 2 years of follow-up, 48 (3%) patients died, 24 (3%) intervention and 24 (4%) 
control. New cardiovascular events were recorded for 97 (7%) patients, 62 (7%) 
intervention and 35 (6%) controls. None of these small differences between intervention 
and control groups were significant. Patients with CHD at baseline were more likely to 
die; 18 (7%) vs. 30 (2%), or to experience CHD events during follow-up 34 (13%) vs. 63 
(5%) irrespective of treatment group. No significant adverse events related to intervention 
were recorded during the study period. 
Results for comparison of outcomes between intervention and control groups are 
presented in Table 2; unadjusted differences compared with a t-test, plus results from 
multiple linear and mixed regression modelling are shown. Comparing treatment groups, 
after two years there was a reduction of 5.1 mmHg in Systolic Blood Pressure (SBP) and 
4.5 mmHg in Diastolic Blood Pressure (DBP) for intervention vs. 4.7 mmHg and 2.9 
mmHg respectively in the control group. T-tests showed significant differences in favour 
of the intervention group for diastolic BP and HbA1c. After adjustment for potential 
confounders DBP and Mean Arterial Pressure (MAP) showed significant advantages for 
the intervention group. In final models taking clustering effects into account, significant 
effects persisted for the intervention group for both MAP and DBP (Table 2).  BMI was 
significantly increased in the intervention group. Other differences in primary and 
secondary outcomes; HbA1c, total cholesterol, waist circumference and CHD risk scores 
were small and not statistically significant after adjustment for confounding and clustering 
(Table 2). 
The percentage of patients with microalbuminuria or proteinuria increased from 28% at 
baseline to 32% after 2 years with no significant difference between the intervention and 
control groups. Patients at high renal risk, defined by plasma creatinine >120 for females 
 - 10 -
and >150 for males increased from 3% at baseline to 4% after 2 years, with no difference 
between treatment groups.  
Combining all patients from intervention and control groups after two years, there was an 
overall decrease of 4.9 (4.0 to 5.9) mmHg in SBP (P<0.001), 3.8 (3.2 to 4.4) mmHg in 
DBP (P<0.001) and 4.2 (3.6 to 4.8) mmHg in MAP (P<0.001). Total cholesterol decreased 
by 0.45 (0.40 to 0.51) mmol/L (P<0.001). A very small and statistically non significant 
increase was observed for HbA1c; 0.04% (-0.04 to 0.13), P=0.2902. 
Prescribing changes and targets achieved 
After two years follow-up, proportions of patients treated with anti-hypertensives had 
increased to 75% overall, with no difference between groups. Treatment with statins had 
increased and the difference between treatment groups disappeared, with 540 (64%) 
intervention vs. 389 (65%) controls treated. The use of ACE inhibitors or Angiotensin 
Receptor Blockers increased substantially from 37% to 65% in the intervention and 40% 
to 62% in the control group; no significant difference between groups.  
Similar proportions of patients were treated with insulin at baseline; 161 (19%) 
intervention and 129 (21%) control. After 2 years, more intervention than control patients 
had started insulin therapy, 47 (8%) vs. 23 (5%), but this was not statistically significant, 
relative risk (RR) 1.44 (0.89 to 2.34).   
The proportion of patients achieving the study targets were; blood pressure (35% v 30%), 
cholesterol ( 48% v 51%) and HbA1c ( 32% v 27%) for intervention and control groups 
respectively. Corresponding proportion of patients achieving the QOF targets for blood 
pressure of < 145/85 mmHg was (66% v 55%), cholesterol <5 mmol/L (81% v 82%) and 
HbA1c <7.5% ( 44% v 39%). 
 
 
 - 11 -
Cost of intervention and quality of life 
A detailed cost breakdown is presented in Table 5. Over two years, the cost of intervention 
per patient was £434 (£406 net service and £28 net prescribing costs). Overall quality of 
life in the studied subjects deteriorated over 2 years. In spite of that, the resultant net 
change in quality of life in the intervention over control group was positive, although 
small. The incremental cost-effectiveness ratio is calculated to be £28,933 per QALY 
gained. 
  
Discussion: 
The achievement of targets set by national and international advisory bodies in general 
practices in inner city areas with a high prevalence of socially diverse ethnic groups poses 
a major challenge12-14, 22. At baseline, a large majority of our patients had HbA1c >7% 
(70%), BP >130/80 (76%) and Total Cholesterol >4 mmol/l (70%); above targets 
recommended by international standards for diabetes care.  After two years in which 
secular changes included the pay for performance initiative there were significant 
improvements in blood pressure and total cholesterol across the whole study population, 
but no change in HbA1c. SBP decreased by 4.9mmHg, DBP by 3.8mmHg and mean 
cholesterol by 0.45 mmol/L. These reductions are both statistically and clinically highly 
significant. A reduction in blood pressure has been associated with rapid reduction in 
cardiovascular risk in many studies23-25. The relationship between blood pressure and 
cardiovascular risk is such that a reduction of 5 mmHg, if sustained would confer 
substantial protection from cardiovascular events26. The improvements in blood pressure 
and cholesterol in our study were associated with increased prescribing of anti 
hypertensive agents and statins and are consistent with improvements reported by several 
others following introduction of the QOF initiatives 27.  
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The mortality observed during the study (3%) together with the baseline (18%) and 
follow-up (7%) frequency of cardiovascular events confirm that the South Asian group we 
studied have a high cardiovascular risk and that substantial benefits could be obtained by 
aggressive risk factor reduction. The failure to prevent the increase in microalbuminuria 
despite a 5mmHg reduction in blood pressure is surprising and suggests that lower targets 
may be needed for this group.  
Comparing intervention and control groups after two years, significant differences were 
observed for diastolic blood pressure and mean arterial pressure after adjustment for 
confounding and clustering. SBP was lower in the intervention group but this was not 
statistically significant. The reductions seen in DBP were comparable to those observed in 
our pilot study but the reduction in SBP was less than previously achieved. It is possible 
that the relatively young age of onset and ethnicity may be a factor in this observation and 
it is interesting that a more pronounced diastolic effect has been reported in some other 
studies28 .   
A small but statistically significant increase in BMI was noted in the intervention group. 
One likely reason for this could be the increased use of insulin in the intervention group 
but other factors such as poor adherence to lifestyle advice may have contributed.  
The lack of improvement in HbA1c may be due, at least in part, to the natural disease 
progression commonly seen in type 2 diabetes29; in the control group HbA1c tended to 
rise while in the intervention group it remained stable over two years..  It is disappointing, 
given the healthcare resources provided, that neither the QOF incentives nor our culturally 
sensitive enhanced care package impacted significantly on glycaemic control.  
Despite clear evidence of failure to reach target levels of HbA1c via diet and oral anti-
diabetic therapy, only a small increase in the percentage of patients treated with insulin 
was observed in both groups (8% vs. 5% for intervention and control groups). Even 
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though the intervention included support from specialist diabetes nurses with experience 
of insulin initiation and enhanced time for patient education, this appears to have had only 
a limited effect in terms of behavioural change or patient acceptance of insulin.  
Initiating insulin in primary care in the UK is relatively new and building up confidence of 
both the health care team and South Asian patients may be as important as any financial 
incentives paid to the former. Changing patient behaviour through motivation and patient 
education might take longer than the two years follow-up in this study. Alternative 
methods of motivation, including structured patient education30 and more aggressive 
insulin initiation, may be needed.  
 
Significant improvements in performance indicators were observed across the UK general 
practice following the introduction of the QOF initiatives and it is likely that even the 
control practices in our study benefited from these changes. Considerably fewer patients 
achieved the study targets compared to those meeting the QOF targets suggesting 
adherence to treatment protocols was poor in both groups. Despite additional nursing 
resources there were small improvements in the intervention group. This may be due to 
reluctance on the part of health professionals and on behalf of patients in their motivation 
to intensify treatments and achieve tighter targets beyond those already set in the QOF 
initiative. Such factors will not be exclusive to South Asians in the UK primary care and 
may be relevant to other racial groups and healthcare settings.  
 
The economic analysis shows that the financial investment required over two years (£434 
per patient) did not produce sufficient health related quality of life gain to make such a 
nurse-led intervention clearly cost-effective. At £28,933 per QALY gained, compared to 
 - 14 -
an indicative norm of £30,000 per QALY31, wide scale implementation is not indicated 
without improvement in effectiveness.  
In our analyses we used LOCF, which we acknowledge has its weaknesses. However, 
analysing complete data only, produced very similar results. A further limitation of our 
study is the inability to assess the relative contributions of individual components of the 
intervention; such difficulties are inherent to evaluation of complex interventions.  
Considerable difficulties in recruiting and retaining individuals of South Asian ethnicity 
have been reported previously by several investigators32, 33 which may account for the lack 
of large scale studies in this area34.  However, our experience indicates that recruitment 
and retention is possible in this hard to reach group.  Our results suggest that small but 
sustained improvements in blood pressure can be achieved through the introduction of a 
culturally sensitive enhanced care package for South Asian patients in addition to 
improvements from the QOF financial incentives. Improving glycaemic control remains a 
major challenge and further work to enhance effectiveness of healthcare delivery in 
general practice and to improve motivation is clearly needed for this group if healthcare 
inequalities are to be reduced.  Whilst progress has been made there remains a substantial 
challenge in achieving the more stringent targets recommended by national and 
international expert advisory bodies.  
 
Word count: 3175 
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Table 1 – Baseline characteristics, Intervention (N=868) vs. Control (N=618) group 
Baseline measure: 
 
Intervention: 
n (%) 
Control: 
n (%) 
Total: 
n (%) 
Gender:  
Female 
Male 
Age group: 
<45 years 
45-64 
65+ 
Duration of diabetes: 
0-4 years 
5-9 
10-19 
20+ 
Treatment: 
Insulin 
Oral 
Diet only 
Smoking status:* 
Current smoker 
Ex smoker 
Non smoker 
 
 
396 (46) 
472 (54) 
 
131 (15) 
467 (54) 
270 (31) 
 
367 (42) 
230 (27) 
197 (23) 
  72 (  8) 
 
161 (19) 
591 (68) 
116 (13) 
 
135 (16) 
  59 (  7) 
673 (78) 
 
 
313 (51) 
304 (49) 
 
 84 (14) 
363 (59) 
171 (28) 
 
222 (36) 
189 (31) 
161 (26) 
 41 (  7) 
 
129 (21) 
429 (69) 
 60 (10) 
 
  86 (14) 
  69 (11) 
462 (75) 
 
 
709 (48) 
776 (52) 
 
215 (14) 
830 (56) 
441 (30) 
 
589 (40) 
419 (28) 
358 (24) 
113 (  8) 
 
290 (20) 
1020 (69) 
176 (12) 
 
221 (15) 
128 ( 9) 
1135 (76) 
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 Weight (kg) 
Waist (cm) 
BMI 
Framingham 10 years 
CHD risk score 
Risk factors profile: 
Mean Arterial Pressure 
(MAP) 
Systolic BP 
Diastolic BP 
Total cholesterol 
HbA1c  
Prescribing: 
All anti-hypertensives 
ACE/ARB 
Statins* 
Mean (s.d.) 
  76.2 (14.6) 
102.0 (11.5)) 
  28.5 (4.8) 
10.5 (8.8) 
 
 
101.7 (12.9) 
 
139.4 (21.1) 
  82.9 (11.0) 
    4.7 (1.1) 
    8.2 (1.9) 
 
475 (55) 
321 (37) 
438 (50) 
Mean (s.d.) 
  75.2 (14.6) 
101.3 (12.3) 
  28.6 (4.9) 
10.6 (8.8) 
 
 
102.9 (12.9) 
 
141.1 (20.3) 
  83.8 (11.1) 
    4.7 (1.1) 
    8.2 (1.8) 
 
342 (55) 
246 (40) 
273 (44) 
Mean (s.d.) 
  75.8 (14.5) 
101.7 (11.8) 
  28.5 (4.9) 
10.6 (8.8) 
 
 
102.2 (12.9) 
 
140.1 (20.8) 
  83.3 (11.0) 
    4.7 (1.1) 
    8.2 (1.9) 
 
817 (55) 
567 (38) 
711 (48) 
 
Missing data: duration of diabetes 7, smoking status 2, weight 2, waist circumference 5, 
BMI 10, total cholesterol 2, HbA1c 13 patients. 
* Statistically significant difference between groups at 5% level 
Smoking status χ² =9.01, P=0.01, Statins χ² =5.72, P=0.02, 
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Table 2. Outcomes, differences (95% confidence intervals) adjusted for potential 
confounding and for clustering: 
Outcomes: (A) Difference 
between means 
(P value) 
(B) Differences least 
squares means 
(P value) 
(C) Differences least 
squares means 
( P value) 
Primary: 
MAP 
 
Systolic BP 
 
Diastolic BP 
 
Total cholesterol 
 
HbA1c 
 
 
-1.23 (-2.52 to 0.05) 
(0.0606) 
-0.43 (-2.33 to 1.48) 
(0.6591) 
-1.63 (-2.80 to -0.46) 
(0.0065) 
0.01 (-0.11 to 0.12) 
(0.8783) 
-0.18 (-0.34 to -0.01) 
(0.0371) 
 
-2.00 ( -3.08 to -0.92) 
(0.0003) 
-1.42 (-3.02 to 0.18) 
(0.0817) 
-2.29 (-3.28 to -1.30) 
(<0.0001) 
0.02 (-0.07 to 0.12) 
(0.6433) 
-0.13 (-0.28 to 0.02) 
(0.0796) 
 
-1.36 (-2.49 to -0.23) 
(0.0180) 
-0.33 (-2.41 to 1.75) 
(0.7577) 
-1.91 (-2.88 to -0.94) 
(0.0001) 
0.03 (-0.04 to 0.11) 
(0.3684) 
-0.15 (-0.33 to 0.03) 
(0.1111) 
Secondary: 
CHD risk (Fram) 
(n=1376)* 
Waist (cm) 
 
BMI 
 
 
0.06 (-0.56 to 0.68) 
(0.8495) 
-0.25 (-0.99 to 0.50) 
(0.5162) 
0.38 (0.20 to 0.55) 
(<0.0001) 
 
-0.08 (-0.62 to 0.46) 
(0.7700) 
-0.06 (-0.76, 0.64) 
(0.8627) 
0.40 (0.22, 0.57) 
(<0.0001) 
 
  0.01 (-0.57 to 0.59) 
(0.9736) 
-0.24 (-1.32, 0.85) 
(0.6657) 
0.40 (0.20, 0.60) 
(<0.0001) 
 
* Note:- Framingham CHD risk only estimated for patients aged 30 to 74 yrs at baseline. 
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 Notes  
(A) crude differences based on t-test comparison, no adjustment. 
(B) differences based on fixed effects model, adjusted for confounding. 
(C) differences based on mixed model, adjusted for confounding and clustering. 
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 Table 3. Intervention costs and incremental cost-effectiveness over 2 years 
 
Intervention costs (incremental cost between intervention & control) 
1. Staff salaries* £224,774
2. Payment to practices(incremental cost between intervention and control 
practices)** 
£50,000
3. Travel and subsistence £17,720
4. Clinical equipment £11,060
Total enhanced diabetes care service over 2 years £303,554
Per patient enhanced service cost over 2 years £406
Prescribing cost (incremental cost between intervention & control) 
Per patient net prescribing cost for non-diabetic drugs over 2 years £16
Per patient net prescribing cost for diabetic drugs over 2 years £12
Per patient net prescribing cost over 2 years £28
Total per patient incremental net cost of intervention over 2 years £434
Per patient quality adjusted life year (QALY) gain over 2 years 0.015 
Incremental cost per QALY gained £28,933  
 
* Staff salaries covered two specialist nurses and five link workers clinical time. The 
salaries included national insurance and pension contributions. 
** It is the net amount paid to nine intervention practices to implement the intervention 
over two years. 
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 Figure 1: Graphic representation of the complex intervention trial. 
 
Timeline Intervention Control 
Month 0 
Randomisation of 
practices  
 
F C F C  
 
Months 1-8 
Recruitment of 
patients and 
Baseline data 
collection 
 
B, C, D 
E 
B, C,  
E  
 
2 monthly research 
clinic 
appointments 
 
B, C, D 
A  
F 
 A, F 
Research 
Monitoring  
meetings (2-3 
months apart) 
 
G, C, D G, C, D 
Months 12- 
20 Outcomes 
assessed 
 
B, C, D 
E 
B, C, D 
E 
A Prescribing algorithms - algorithms for blood pressure, blood glucose and lipid 
control (Appendix 1) 
 
B Practice Nurse (works in a GP Surgery as a part of primary health care team)- 
protected time to run research diabetes clinic in intervention practices. Dietary 
advice and implementation of protocols. Practice nurses were formally trained 
in Diabetes and had 1:1 observed sessions with Diabetes Specialist Nurse  
 
C Diabetes Specialist Nurse (Nurse with specialist knowledge of management of 
Diabetes; usually works in a hospital setting) - clinical input including insulin 
initiation and educational role. Attendance at some, but not necessarily all 
research clinics. Two specialist nurses were responsible for all 21 practices in 
the trial, one based in Coventry and one in Birmingham. 
 
D Link Workers - educational, communication and facilitation role, promoting 
patients’ understanding and concordance. Link Workers attended research 
clinics in intervention practices. A total of 5 Link Workers were employed, 3 in 
Birmingham (14 practices) and 2 in Coventry (7 Practices), with each 
responsible for 3 or more practices. All link workers attended a foundation 
course in Diabetes management (equivalent to diploma ) in Diabetes Care. 
 
E Questionnaires for patients – Quality of Life (EQ5D), and economic analysis 
data collection. 
 
F General Practitioners - overall responsibility for implementation of the 
study protocol within their practice. This was mainly devolved to the 
responsible Practice Nurse. GPs were involved in changing prescribing 
processes. 
 
G Research team - oversaw study processes. Meetings to monitor recruitment 
and data collection, to discuss and address issues of study conduct and 
management.  
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Figure 2 – Practice and patient recruitment and progress through the trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total patients recruited from 21 general practices  
                         1486 
Practices and patients randomised 
 
Intervention 868 Control 618 
(9 Practices)  (12 Practices)
  
Intention to treat analysis patients:  
1486 (100%) 
 
Intervention 868  Control 618 
 
(9 Practices)  (12 Practices)
21 general practices  
(7 Coventry and 14 Birmingham) 
 
 
No follow-up data: 
Lost     79 
Too ill to attend   20 
Refused    61 
Died     48 
 
Total   208 (14%) 
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